A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (TransIT)

April 11, 2024 updated by: David Williams, Boston Children's Hospital

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia).

This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA.

The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms.

This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is a multi-center randomized phase III trial to compare the failure free survival between those randomized to IST vs 9-10/10 HLA matched URD BMT. The study will also address patient-reported outcomes and gonadal function in each arm and explore critical biological correlates including assessing germline genetic mutations associated with pediatric SAA that may lead to a predisposition to the disease and the risk of development of clonal hematopoiesis following IST vs BMT in pediatric and young adult SAA.

This clinical trial will randomize 234 children/AYA over 3.3-4.7 years at a 1:1 ratio between initial treatment with immune suppression therapy (IST) with horse ATG (hATG)/cyclosporine (CsA) versus well- matched (9-10/10 allele) unrelated donor (URD) bone marrow transplantation (BMT) using a regimen of rabbit ATG (rATG)/fludarabine/cyclophosphamide and 200 cGy TBI. Duration of subject participation for all study procedures in this study will be up to 2 years after treatment; a single later timepoint between 3 and 5 years will be collected to follow patients for specific protocol defined late effects and survival.

Study Type

Interventional

Enrollment (Estimated)

234

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35249
        • Recruiting
        • University of Alabama at Birmingham
        • Contact:
    • Arizona
    • California
      • Los Angeles, California, United States, 90027
      • Los Angeles, California, United States, 90095
      • Oakland, California, United States, 94609
        • Recruiting
        • Children's Hospital & Research Center Oakland
        • Contact:
      • Orange, California, United States, 92868
        • Recruiting
        • Children's Hospital of Orange County
        • Contact:
      • Palo Alto, California, United States, 94304
      • San Diego, California, United States, 92123
        • Recruiting
        • Rady Children's Hospital San Diego
        • Contact:
      • San Francisco, California, United States, 94158
    • Colorado
    • Connecticut
    • Delaware
      • Wilmington, Delaware, United States, 19803
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
    • Florida
      • Gainesville, Florida, United States, 32610
      • Miami, Florida, United States, 33155
      • Saint Petersburg, Florida, United States, 33701
        • Recruiting
        • Johns Hopkins All Children's Hospital
        • Contact:
    • Georgia
      • Atlanta, Georgia, United States, 30322
    • Illinois
      • Chicago, Illinois, United States, 60637
      • Chicago, Illinois, United States, 60611
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Recruiting
        • Indiana University Hospital/Riley Hospital for Children
        • Contact:
    • Louisiana
      • New Orleans, Louisiana, United States, 70118
        • Recruiting
        • Children's Hospital NOLA
        • Contact:
    • Maine
      • Scarborough, Maine, United States, 04074
    • Massachusetts
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
      • Grand Rapids, Michigan, United States, 49503
    • Mississippi
      • Jackson, Mississippi, United States, 39216
        • Recruiting
        • University of Mississippi Medical Center
        • Contact:
    • Missouri
      • Saint Louis, Missouri, United States, 63110
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
    • New York
      • Buffalo, New York, United States, 14263
      • New Hyde Park, New York, United States, 11040
        • Recruiting
        • Cohen Children's Medical Center of New York
        • Contact:
      • New York, New York, United States, 10032
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • Recruiting
        • University of North Carolina
        • Contact:
      • Charlotte, North Carolina, United States, 28203
      • Durham, North Carolina, United States, 27705
    • Ohio
    • Oregon
      • Portland, Oregon, United States, 97239
        • Recruiting
        • Oregon Health & Science University
        • Contact:
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Recruiting
        • Children's Hospital of Philadelphia
        • Contact:
    • Tennessee
      • Memphis, Tennessee, United States, 38105
      • Nashville, Tennessee, United States, 37203
    • Texas
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Recruiting
        • University of Utah/Primary Children's Hospital
        • Contact:
    • Washington
      • Seattle, Washington, United States, 98109
    • Wisconsin
      • Madison, Wisconsin, United States, 53792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second to 25 years (Child, Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

To be eligible to participate in the randomized trial, an individual must meet all the following criteria:

  1. Provision of signed and dated informed consent form for the randomized trial by patient and/or legal guardian.
  2. Age ≤25 years old at time of randomized trial consent.

  3. Confirmed diagnosis of idiopathic SAA, defined as:

    1. Bone marrow cellularity <25%, or <30% hematopoietic cells.
    2. Two of three of the following (in peripheral blood): neutrophils <0.5 x 10^9/L, platelets <20 x 10^9/L, absolute reticulocyte count <60 x 10^9/L or hemoglobin <8 g/dL.
  4. No suitable fully matched related donor available (minimum 6/6 match for HLA-A and B at intermediate or high resolution and DRB1 at high resolution using DNA based typing).
  5. At least 2 unrelated donors noted on NMDP search who are well matched (9/10 or 10/10 for HLA-A, B, C, DRB1, and DQB1 using high resolution).
  6. In the treating physician's opinion, no obvious contraindications precluding them from BMT or IST.

Exclusion Criteria:

  1. Presence of Inherited bone marrow failure syndromes (IBMFS). The diagnosis of Fanconi anemia must be excluded by diepoxybutane (DEB) or equivalent testing on peripheral blood or marrow. Telomere length testing should be sent on all patients to exclude Dyskeratosis Congenita (DC), but if results are delayed or unavailable and there are no clinical manifestations of DC, patients may enroll. If patients have clinical characteristics suspicious for Shwachman-Diamond syndrome, this disorder should be excluded by pancreatic isoamylase testing or gene mutation analysis (note: pancreatic isoamylase testing is not useful in children <3). Other testing per center may be performed to exclude IBMFS.
  2. Clonal cytogenetic abnormalities or Fluorescence In-Situ Hybridization (FISH) pattern consistent with pre- myelodysplastic syndrome (pre-MDS) or MDS on marrow examination.
  3. Known severe allergy to ATG.
  4. Prior allogeneic or autologous stem cell transplant.
  5. Prior solid organ transplant.
  6. Infection with human immunodeficiency virus (HIV).
  7. Active Hepatitis B or C. This only needs to be excluded in patients where there is clinical suspicion of hepatitis (e.g., elevated LFTs).
  8. Female patients who are pregnant or breast-feeding.
  9. Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ.
  10. Disease modifying treatment prior to study enrollment, including but not limited to use of androgens, eltrombopag, romiplostim, or immune suppression. Note: Supportive care measures such as G-CSF, blood transfusion support and antibiotics are allowable

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Immunosuppressive Therapy
Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
Drug: cyclosporine
cyclosporine
Drug: horse anti-thymocyte globulin (ATG)
horse anti-thymocyte globulin (ATG)
Other Names:
  • ATGAM
Procedure: Immunosuppressive Therapy (IST)
Immunosuppressive Therapy (IST)
Active Comparator: Matched Unrelated Stem Cell Transplant
Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
Drug: Cyclophosphamide
cyclophosphamide
Drug: cyclosporine
cyclosporine
Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant
Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
Drug: rabbit anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG)
Other Names:
  • thymoglobulin
Drug: Methotrexate
methotrexate
Drug: Fludarabine
fludarabine
Radiation: low-dose total body irradiation (TBI)
low-dose total body irradiation (TBI)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The primary endpoint of this trial is time from randomization to treatment failure or death from any cause.
Time Frame: Randomization to 2 years post-randomization
The median time to failure or death will be compared on the two arms using the log-rank test. Failure of IST is defined as the date that a second definitive therapy was recommended (BMT, second course of ATG) and failure of BMT defined as the date that a second definitive therapy was recommended (second BMT, course of ATG).
Randomization to 2 years post-randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of subjects with failure of IST or BMT before or at 2 years
Time Frame: Randomization to 2 years post-randomization
The proportion of subjects with failure of IST or BMT before or at 2 years. Failure of IST is defined as initiation of a second definitive therapy (BMT, second course of ATG) and failure of BMT defined as initiation of a second definitive therapy (second BMT, course of ATG).
Randomization to 2 years post-randomization
Comparison of subjects with inadequate counts at 2 years among those who have not died or failed treatment.
Time Frame: Randomization to 2 years post-randomization
The proportion of subjects with inadequate counts at 2 years among those who have not failed therapy or died. Adequate counts are defined as: Absolute Neutrophil Count (ANC) >1 x 10^9/L, Hemoglobin >10g/dL, and Platelets >50 x10^9/L.
Randomization to 2 years post-randomization
Comparison of subjects on immune suppression therapy at 2 years among those who have not died or failed treatment.
Time Frame: Randomization to 2 years post-randomization
The proportion of subjects on immune suppression therapy at 2 years among those who have not failed therapy or died. Immune suppression is defined as systemic therapies necessary to treat SAA or GVHD (cyclosporine, tacrolimus, etc.). Isolated treatment with topical agents will not be considered as immune suppression therapy.
Randomization to 2 years post-randomization
Estimate the time from randomization to initiation of IST or BMT.
Time Frame: Randomization through Day 100
The median time in days from randomization to initiation of IST or BMT will be estimated. Initiation of therapy is first day of ATG for IST subjects, or day 0 (infusion day) for bone marrow transplant subjects.
Randomization through Day 100
Comparison of the frequency of failure to receive primary assigned therapy (IST or BMT) and reasons for the failure.
Time Frame: Randomization through Day 100
The proportion of subjects who fail to receive randomized therapy and the frequency of reasons for failure.
Randomization through Day 100
Comparison of the incidence of bacteremia, viremia, and invasive fungal infection in the first two years after randomization in the IST and BMT arms.
Time Frame: Randomization through two years post randomization

Proportion of subjects from the time of randomization in the first 2 years with each of the following:

  1. Documented bacteremia
  2. Documented viremia
  3. Documented invasive fungal infection (defined as confirmed or suspected fungal infection based upon imaging)
Randomization through two years post randomization
Estimate the median time to T- and B-cell immune reconstitution the first year for the URD BMT Arm
Time Frame: Initiation of therapy (Day 0) to 100 days, 180 days, 1 year and 2 years
Absolute CD3, CD4, CD8, CD19, and CD56 (NK cell) numbers will be tracked at 100 days, 180 days, 1 year and 2 years post initiation of therapy in URT BMT arm. IgG levels free of IVIG replacement will be collected at the same timepoints. The median time to T- and B-cell reconstitution will be estimated.
Initiation of therapy (Day 0) to 100 days, 180 days, 1 year and 2 years
Comparison of overall survival at 1 and 2 years from randomization in both arms.
Time Frame: Randomization to one year, randomization to two years
Proportion of subjects who have died at 1 year and 2 years after randomization for any reason.
Randomization to one year, randomization to two years
Comparison of treatment-related mortality (TRM) at 1 and 2 years from randomization in both arms.
Time Frame: Randomization to 1 year, randomization to 2 years
Proportion of subjects who have died at 1 year and 2 years after randomization due to treatment-related reasons. TRM is defined as death in recipients without relapse or progression of their disease. Non-medical, accidental causes of death, e.g., natural disasters, are not considered TRM.
Randomization to 1 year, randomization to 2 years
Comparison of the median time from randomization to and rates of neutrophil recovery on both arms
Time Frame: Randomization to 100 days, 180 days, 1 year and 2 years
The time from randomization to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).
Randomization to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from initiation of therapy to and rates of neutrophil recovery on both arms
Time Frame: Initiation of therapy to 100 days, 180 days, 1 year and 2 years
The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to neutrophil recovery. Neutrophil recovery is defined as ANC 0.5 x109/L for 3 consecutive measures for neutrophils (recovery date is the first date).
Initiation of therapy to 100 days, 180 days, 1 year and 2 years
Estimate the rates of engraftment in patients who are randomized to URD BMT.
Time Frame: Randomization to 3-5 years
Proportion of subjects with engraftment in patients who receive URD BMT.
Randomization to 3-5 years
Estimate the rates of primary graft failure in patients who are randomized to URD BMT .
Time Frame: Randomization to 3-5 years
Proportion of subjects with primary graft failure in patients who receive URD BMT. Primary graft failure is defined as failure to achieve neutrophil recovery by Day +28 following a conditioning regimen induced neutrophil nadir < 0.5 x10^9/L.
Randomization to 3-5 years
Estimate the rates of secondary graft failure in patients who are randomized to URD BMT .
Time Frame: Randomization to 3-5 years
Proportion of subjects with secondary graft failure in patients who receive URD BMT. Secondary graft failure will be defined as a fall in the neutrophil count after documented primary engraftment to < 0.5 x10^9/L sustained for more than three days that cannot be attributed to other causes such as drugs, infection, GVHD, etc., and is not responsive to G-CSF or GM-CSF.
Randomization to 3-5 years
Estimate the rates of grade II-IV acute GVHD in patients who are randomized to URD BMT .
Time Frame: Randomization to 3-5 years
Proportion of subjects with grade II-IV in patients who receive URD BMT.
Randomization to 3-5 years
Estimate the rates of grade III-IV acute GVHD in patients who are randomized to URD BMT.
Time Frame: Randomization to 3-5 years
Proportion of subjects with grade III-IV acute GVHD in patients who receive URD BMT.
Randomization to 3-5 years
Estimate the rates of failure of patients randomized to IST
Time Frame: Randomization to 100 days, 180 days, 1 year and 2 years
Proportion of subjects with IST failure at 6 months (defined as Hemoglobin <8 g/dL or ANC <0.5x10^9/L or Platelets <20x10^9/L).
Randomization to 100 days, 180 days, 1 year and 2 years
Describe the secondary therapies given and outcomes achieved for patients failing initial therapy
Time Frame: Randomization to 3-5 years
Collect secondary therapies given for failure of primary randomized therapy (BMT after IST, second course of IST, second BMT). For the outcome after subsequent therapy, the median survival time will be estimated.
Randomization to 3-5 years
Comparison of rates of secondary MDS, AML, other subsequent neoplasms, and development of Paroxysmal Nocturnal Hemoglobinuria in both treatment arms for the duration of the trial.
Time Frame: Randomization to 3-5 years
Proportion of subjects in each treatment arm with i) subsequent neoplasms, ii) presence of a PNH clone at time of randomization who go on to develop symptomatic PNH through the duration of the protocol.
Randomization to 3-5 years
Comparison of HR-QoL score between patients randomized to both arms
Time Frame: Randomization to 2 years post-randomization, randomization to up to 5 years post-randomization
Change in score between baseline and two years and the trajectory of change over all timepoints.
Randomization to 2 years post-randomization, randomization to up to 5 years post-randomization
Comparison of gonadal function values between patients randomized to both arms
Time Frame: Randomization to 1 year post-randomization, randomization to 2 years post-randomization, and randomization to up to 5 years post-randomization
Proportion of subjects with gonadal function values outside the expected percentile for that age.
Randomization to 1 year post-randomization, randomization to 2 years post-randomization, and randomization to up to 5 years post-randomization
Comparison of the median time from randomization to and rate of platelet recovery on both arms
Time Frame: Randomization to 100 days, 180 days, 1 year and 2 years
The time from randomization to platelet recovery. Platelet recovery is defined as platelet levels >= 20 x10^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.
Randomization to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from randomization to and rates of red blood cell recovery on both arms
Time Frame: Randomization to 100 days, 180 days, 1 year and 2 years
The time from randomization to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level >= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.
Randomization to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from initiation of therapy to and rate of platelet recovery on both arms
Time Frame: Initiation of therapy to 100 days, 180 days, 1 year and 2 years
The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to platelet recovery. Platelet recovery is defined as platelet levels >= 20 x10^9/L for 3 consecutive measures (recovery is the first date) with no platelet transfusions for 1 full week.
Initiation of therapy to 100 days, 180 days, 1 year and 2 years
Comparison of the median time from initiation of therapy to and rates of red blood cell recovery on both arms.
Time Frame: Randomization to 100 days, 180 days, 1 year and 2 years
The time from initiation of therapy (defined as Day 1 for patients randomized to IST and Day 0 for patients randomized to URD BMT) to red blood cell recovery. Red blood cell recovery is defined as RBC hemoglobin level >= 8g/dL and 10g/dL with no RBC transfusions for 4 weeks.
Randomization to 100 days, 180 days, 1 year and 2 years
Estimate the rates of response of patients randomized to IST
Time Frame: Randomization to 100 days, 180 days, 1 year and 2 years

Proportion of subjects with IST response. IST response criteria is:

Complete Response: Hemoglobin ≥10 g/dL and ANC ≥1x10^9/L and Platelets ≥100x10^9/L Very Good Partial Response: Hemoglobin ≥8 g/dL and ANC ≥0.5x10^9/L and Platelets ≥50x10^9/L Partial Response: Hemoglobin ≥8 g/dL and ANC ≥0.5x10^9/L and Platelets ≥20x10^9/L and transfusion independent No Response (failure): Hemoglobin <8 g/dL or ANC <0.5x10^9/L or Platelets <20x10^9/L Lost Response: A lost response is captured by not meeting hematologic response criteria at a particular time point after having an initial response (complete, very good partial, or partial), or the need for additional treatment.
Randomization to 100 days, 180 days, 1 year and 2 years
Estimate the rates of severe chronic GVHD in patients who are randomized to URD BMT.
Time Frame: Randomization to 3-5 years
Proportion of subjects with severe chronic GVHD in patients who receive URD BMT.
Randomization to 3-5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boston Children's Hospital

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Center for International Blood and Marrow Transplant Research
Blood and Marrow Transplant Clinical Trials Network
North American Pediatric Aplastic Anemia Consortium
Pediatric Transplantation and Cellular Therapy Consortium

Investigators

  • Principal Investigator: David Williams, MD, Boston Children's Hospital
  • Principal Investigator: Michael Pulsipher, MD, University of Utah
  • Principal Investigator: Bronwen Shaw, MD, CIBMTR/Medical College of Wisconsin (MCW)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 25, 2023

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

October 20, 2022

First Submitted That Met QC Criteria

October 26, 2022

First Posted (Actual)

October 31, 2022

Study Record Updates

Last Update Posted (Actual)

April 12, 2024

Last Update Submitted That Met QC Criteria

April 11, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-2020-0438
  • 1UG3HL157564-01A1 (U.S. NIH Grant/Contract)
  • 1U24HL157560-01A1 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Severe Aplastic Anemia

Clinical Trials on Cyclophosphamide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe